Health Care • Biotechnology: Pharmaceutical Preparations
$3.33 ▲ +0.22
(+7.07%)
MKT CAP: $2.5M • VOL: 183.4K
52W L $3 52W H $464
SBFM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $36.3M | $34.9M | $24.1M |
| YoY Revenue Growth % | +4.1% | +44.7% | — |
| Gross Profit | $12.3M | $10.7M | — |
| Gross Margin % | 33.8% | 30.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.2M | -$5.8M | -$4.8M |
| Operating Margin % | -17.2% | -16.7% | -19.9% |
| Net Income (GAAP) | -$6.0M | -$5.1M | -$4.5M |
| EBITDA (Normalized) | -$6.1M | -$4.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.3M | -$12.5M | -$8.8M |
| Capital Expenditures (CapEx) | $174.5K | $1.7M | — |
| Free Cash Flow (FCF) | -$5.5M | -$14.2M | -$8.8M |
| FCF Margin % | -15.2% | -40.7% | -36.4% |
| Return on Invested Capital (ROIC %) | -21.4% | -19.5% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $23.0M | $23.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SBFM.